Patents by Inventor Philipp Heller

Philipp Heller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230049655
    Abstract: The present disclosure generally relates to therapies involving immune effector cells such as T cells engineered to express antigen receptors such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). It is demonstrated herein that such antigen receptor-engineered immune effector cells may be generated in vitro/ex vivo as well as in vitro by delivering nucleic acid encoding an antigen receptor for genetic modification to cells using particles comprising the nucleic acid and a targeting molecule for targeting the immune effector cells, wherein the targeting molecule is a designed ankyrin repeat protein (DARPin). In particular, DARPins are described herein which are high-affinity binders for CDS binding to the CDS receptor on human and non-human primate (NHP) cells. Nanoparticles functionalized with CD8? targeting DARPins (CDS-DARPin) can deliver genes exclusively and specifically to human CD8+ T cells in vitro and in vivo.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 16, 2023
    Inventors: Annika FRANK, Jessica HARTMANN, Christian BUCHHOLZ, Benjamin RENGSTL, Arne Marten BILLMEIER, Ugur SAHIN, Hans-Ulrich SCHMOLDT, Philipp HELLER, Bonny Gaby LUI, Anne SCHLEGEL
  • Publication number: 20220001025
    Abstract: The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The RNA particles in one embodiment comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity.
    Type: Application
    Filed: September 30, 2019
    Publication date: January 6, 2022
    Inventors: Matthias Barz, Benjamin Weber, Heinrich Haas, Philipp Heller, Sara Nogueira, Anne Schlegel